Wobenzym Research

Wobenzym Research

Research is continuously being completed concerning the health benefits of Wobenzym. One study was performed to evaluate the effect of Wobenzym enzymes on the atherogenic potential and inflammatory factors at the rehabilitation stage for patients who had a myocardial infarct. The effects of Wobenzym on the atherogenicity of blood serum were evaluated as well as the immuno-inflammatory reaction of patients with myocardial infarction. The study was performed during the rehabilitation stage over a six month period of time. The basis therapy for the patients supplemented with Wobenzym showed facilitation of the normalization of the atherogenic potential. It also had a positive effect on the mediators of the inflammatory process.
(Lik Sprava. 2000 Jul-Aug;(5):111-4)

Another study was performed to determine the efficacy of Wobenzym in the comprehensive treatment of patients with a digital flexor tendon injury. The study evaluated 56 patients with digital flexor tendon injuries. The study isolated 28 of the patients and treated them with Wobenzym along with their other complex treatment as well as early active mobilization. Considerable anti-inflammatory and anti-oedematous effects were noted. A secondary analgesic effect was also noted and patients taking Wobenzym were able to regain active movements earlier.
(Klin Khir. 2000;(4):39-40.)

As Wobenzym continues to be assessed for its many health benefits, the research shows even more uses for Wobenzym in helping treat diseases and conditions. A study performed in 1999 looked at the effect of the Wobenzym preparation on the antioxidant protection indices and on the functional-morphological properties of the erythrocytes in a toxic lesion of the liver. The study examined 60 patients with toxic afflictions of the liver. The anti-radical defense decompensation mechanisms were established together with changes in morphofunctional properties of red cells in toxic hepatitis in patients with pulmonary tuberculosis. It was considered expedient to include the polyenzymic preparation, Wobenzym, into the therapeutic complex since it had been shown to make for normalization of the red cells ability to undergo deformation, lowering the degree of viscosity of RBC suspension in the patients.
(Lik Sprava. 1999 Jul;(5):124-8.)

A study was completed investigating Wobenzym and diuretic therapy in lymphedema after breast operation. The authors of this clinical study report the results of a controlled clinical trial in randomized parallel groups (Wobenzym vs. diuretics) of 55 female patients suffering from brachial arm lymph edema subsequent to ablatio mammae. All patients received manual and machine lymph drainage as well as gymnastics as concomitant therapy. After 7 weeks of therapy the results of the volometric assessments of the arm, the circumference of the arm and the skin fold thickness showed significant improvements compared to diuretics. In addition, the patients receiving Wobenzym reported a significantly higher proportion of patients free of pain compared to the diuretics patients. Overall safety assessment results are satisfactory thus resulting in a superior benefit/risk relation of the Wobenzym group.
(Wien Med Wochenschr. 1996;146(4):67-72; discussion 74.)

This next study looks at the effects of Wobenzym on the blood proteinase-inhibitory system in elderly and senile patients with gastric and duodenal peptic ulcers. The study was made in 31 patient with gastric and duodenal peptic ulcer aged from 60 to 82 years. It has been ascertained that exacerbation of the condition is accompanied by decline in the lysis of azoalbumin (low-molecular proteins), by a decrease in the blood serum concentration of alpha 2-macroglobulin in the presence of an increased lysis of azocol (colagenolytic activity of the blood) and the blood serum content of aldehyde and ketone derivatives. Administration of Wobenzym and erbisol against the background of a differentiated basic therapy makes for improvement of the condition of the blood proteinase-inhibitory system, with the protein oxidative modification processes being on the decrease.
(Lik Sprava. 2001 May-Jun;(3):130-5.)

One other study shows Intestinal resorption with 3H labeled enzyme mixture (wobenzyme). 0.2 g of an enzyme mixture, Wobenzym, labeled with 3H-acetic anhydride, were given orally to guinea pigs, which were arranged in 4 groups of 5 animals. The animals of each group were sacrificed at intervals of 30 minutes, 2, 4 and 24 hours after application. Radioactivity of the small and large intestine, plasma, urine, liver, heart, kidney, and skeletal muscle were determined. It could be shown that the labeled mixture of enzymes was absorbed from the intestine and was demonstrable in significant amounts in plasma, urine, heart, kidney, liver and skeletal muscle.
(Acta Med Austriaca. 1979;6(1):13-8.)

Wobenzym N Ingredients and Wobenzym Dosage Information

Wobenzym N by Naturally Vitamins is the world s most researched systemic enzyme therapy preparation. Decades of research and dedication have gone into enzyme study so that the Wobenzym product could be made available to the millions of people world-wide who need its healing properties. Wobenzym s impact on a variety of health issues continues to be assessed as researchers are constantly discovering more benefits its proteolytic enzymes have to offer. Wobenzym effectively reduces inflammation and can be a valuable aid in preventing and treating degenerative diseases. It is widely recognized for its ability to improve health for those suffering with osteo-arthritis or some autoimmune disorders such as fibromyalgia and polymyalgia. It is also used commonly by athletes to help prevent injuries and to recover from physical injury more quickly. Similarly, physicians often use Wobenzym to help patients heal from surgery or other traumatic procedures more quickly. Wobenzym provides support for healthy digestion of fats, carbohydrates, and fibers. It improves intestinal health and enhances metabolism. Wobenzym increases healthy blood flow and red blood cell count. It has been recognized for its anti-coagulation properties. For this reason, it has shown to reduce strokes and heart attacks. Wobenzym is also used in conjunction with cancer therapies to improve quality of life for cancer patients and to help fight certain cancers. Wobenzym contains the following:

3 Tablets Contain: